Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs HLT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HLT's multiple
Needs HLT P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · HLT FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
Hilton Worldwide Holdings Inc. · implied price per share
Bear
$66.02
Base
$77.67
Bull
$89.32
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
-2.30x
Net debt / EBITDA
Leverage against operating earnings
0.01x
3.21x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$918.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
MARRIOTT INTERNATIONAL INC /MD/
SRPT vs MAR
Hyatt Hotels Corp
SRPT vs H
CHOICE HOTELS INTERNATIONAL INC /DE
SRPT vs CHH
HOST HOTELS & RESORTS, INC.
SRPT vs HST
LAS VEGAS SANDS CORP
SRPT vs LVS
MGM Resorts International
SRPT vs MGM
$934.46M
$12.38B
Live quote
Price unavailable
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can sustainably convert its 15.6% revenue growth into positive margins and improve quality scores from 2/9, then SRPT could be a value opportunity; otherwise, the stock likely remains cheap for valid fundamental reasons because profitability and distress metrics are still weak.
SRPT's current price of $19.28 is far below HLT-implied price of $133.87, implying 594.3% upside on the stated P/S framework. However, that gap is driven by a comparison to HLT's much richer revenue multiple rather than by superior SRPT fundamentals.
Supporting Metrics
